Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XII.f

Cardiomyopathy (acute, subacute, chronic)

Publications

Toro-Salazar OH, Gillan E, O'Loughlin MT, Burke GS, Ferranti J, Stainsby J, Liang B, Mazur W, Raman SV, Hor KN

Occult cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy.

Circulation. Cardiovascular imaging. 2013;6(6):873-80

Sawyer DB

Anthracyclines and heart failure.

The New England journal of medicine. 2013;368(12):1154-6

Hayek ER, Speakman E, Rehmus E

Acute doxorubicin cardiotoxicity.

The New England journal of medicine. 2005;352(23):2456-7

Unverferth BJ, Magorien RD, Balcerzak SP, Leier CV, Unverferth DV

Early changes in human myocardial nuclei after doxorubicin.

Cancer. 1983;52(2):215-21

Parrillo JE, Aretz HT, Palacios I, Fallon JT, Block PC

The results of transvenous endomyocardial biopsy can frequently be used to diagnose myocardial diseases in patients with idiopathic heart failure. Endomyocardial biopsies in 100 consecutive patients revealed a substantial incidence of myocarditis.

Circulation. 1984;69(1):93-101

Hortobagyi GN, Frye D, Buzdar AU, Ewer MS, Fraschini G, Hug V, Ames F, Montague E, Carrasco CH, Mackay B

Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma.

Cancer. 1989;63(1):37-45

Bristow MR, Mason JW, Billingham ME, Daniels JR

Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization.

Annals of internal medicine. 1978;88(2):168-75

Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM

Risk factors for doxorubicin-induced congestive heart failure.

Annals of internal medicine. 1979;91(5):710-7